- 理想的成長型公司, 本業EPS的成長幅度會大於營收的成長幅度
- 營收到某個數字後, 本業EPS呈現不成比例的增加, 有可能是規模經濟的效應
- 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
- 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
- 如果EPS衰退，要觀察同業是不是有一樣的狀況
- 要留意增資減資和公司債對股本及EPS的影響
| 加權平均股數 QoQ YoY | EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | 營收 QoQ YoY | 毛利率(%) QoQ YoY | 營業利益率 QoQ YoY | 稅後淨利率 QoQ YoY | 營業利益 QoQ YoY | 稅後淨利 QoQ YoY | 稅前淨利率(%) QoQ YoY | 稅後淨利率(%) QoQ YoY | 兩季平均(YOY)營收成長率(%) | 兩季平均(YOY)EPS成長率(%) | 兩季平均(YOY)本業EPS成長率(%) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | 260 | 0.0 | -0.76 | 2.18 | -49.42 | -60.15 | 6.92 | 38.68 | 27.91 | 2.18 | -87.98 | -60.15 | 86.44 | 38.04 | 82.75 | 50.73 | -8.28 | -17.7 | 22.66 | -4.95 | -37.49 | 6.56 | -63.37 | -78.39 | 19.59 | 31.21 | 14.23 | 5.67 | -49.47 | -60.49 | 8.40 | -60.04 | -77.2 | 6.56 | -63.37 | -78.39 | 34.64 | -35.74 | 50.88 |
| 25Q4 (7) | 260 | 0.39 | -0.76 | 4.31 | -22.06 | -0.46 | 4.99 | 63.07 | 97.23 | 18.14 | 31.26 | -6.25 | 62.62 | 31.25 | 42.03 | 55.31 | -3.51 | 0.51 | 23.84 | -4.64 | 3.16 | 17.91 | -40.44 | -30.28 | 14.93 | 25.15 | 46.52 | 11.22 | -21.81 | -0.97 | 21.02 | -45.27 | -37.98 | 17.91 | -40.44 | -30.28 | 15.88 | 37.37 | 9.87 |
| 25Q3 (6) | 259 | -0.38 | -1.15 | 5.53 | 96.8 | -7.53 | 3.06 | -43.33 | -55.26 | 13.82 | 66.71 | -8.05 | 47.71 | 0.51 | -8.85 | 57.32 | -2.58 | -9.5 | 25.00 | -21.09 | -38.06 | 30.07 | 96.02 | 0.57 | 11.93 | -20.68 | -43.51 | 14.35 | 97.12 | -8.31 | 38.41 | 120.37 | 5.93 | 30.07 | 96.02 | 0.57 | 0.43 | 24.08 | -21.75 |
| 25Q2 (5) | 260 | -0.76 | -0.76 | 2.81 | -48.63 | -44.79 | 5.40 | -0.18 | 7.57 | 8.29 | 51.55 | -8.4 | 47.47 | 0.36 | 0.08 | 58.84 | -4.54 | -3.06 | 31.68 | -12.61 | -7.99 | 15.34 | -49.46 | -45.35 | 15.04 | -12.3 | -7.9 | 7.28 | -49.27 | -45.35 | 17.43 | -52.69 | -50.23 | 15.34 | -49.46 | -45.35 | - | - | 0.00 |
| 25Q1 (4) | 262 | 0.0 | 0.0 | 5.47 | 26.33 | 0.0 | 5.41 | 113.83 | 0.0 | 5.47 | -71.73 | 0.0 | 47.3 | 7.28 | 0.0 | 61.64 | 12.01 | 0.0 | 36.25 | 56.86 | 0.0 | 30.35 | 18.14 | 0.0 | 17.15 | 68.3 | 0.0 | 14.35 | 26.65 | 0.0 | 36.84 | 8.7 | 0.0 | 30.35 | 18.14 | 0.0 | - | - | 0.00 |
| 24Q4 (3) | 262 | 0.0 | 0.0 | 4.33 | -27.59 | 0.0 | 2.53 | -63.01 | 0.0 | 19.35 | 28.74 | 0.0 | 44.09 | -15.76 | 0.0 | 55.03 | -13.12 | 0.0 | 23.11 | -42.74 | 0.0 | 25.69 | -14.08 | 0.0 | 10.19 | -51.75 | 0.0 | 11.33 | -27.6 | 0.0 | 33.89 | -6.54 | 0.0 | 25.69 | -14.08 | 0.0 | - | - | 0.00 |
| 24Q3 (2) | 262 | 0.0 | 0.0 | 5.98 | 17.49 | 0.0 | 6.84 | 36.25 | 0.0 | 15.03 | 66.08 | 0.0 | 52.34 | 10.35 | 0.0 | 63.34 | 4.35 | 0.0 | 40.36 | 17.22 | 0.0 | 29.90 | 6.52 | 0.0 | 21.12 | 29.33 | 0.0 | 15.65 | 17.49 | 0.0 | 36.26 | 3.54 | 0.0 | 29.90 | 6.52 | 0.0 | - | - | 0.00 |
| 24Q2 (1) | 262 | 0.0 | 0.0 | 5.09 | 0.0 | 0.0 | 5.02 | 0.0 | 0.0 | 9.05 | 0.0 | 0.0 | 47.43 | 0.0 | 0.0 | 60.70 | 0.0 | 0.0 | 34.43 | 0.0 | 0.0 | 28.07 | 0.0 | 0.0 | 16.33 | 0.0 | 0.0 | 13.32 | 0.0 | 0.0 | 35.02 | 0.0 | 0.0 | 28.07 | 0.0 | 0.0 | - | - | 0.00 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/4 | 30.86 | -29.13 | 19.91 | 117.3 | 60.61 | 96.78 | N/A | 主要係受惠於併購NAGH後的營收挹注及出口業務成長所致 | ||
| 2026/3 | 43.54 | 94.54 | 173.55 | 86.44 | 82.76 | 86.44 | 1.07 | 主要係受惠於併購NAGH後的營收挹注及出口業務成長所致 | ||
| 2026/2 | 22.38 | 9.07 | 131.52 | 42.9 | 36.71 | 67.32 | 1.37 | 主要係併購取得NAGH後，受惠於其營收挹注所致 | ||
| 2026/1 | 20.52 | -15.97 | -5.49 | 20.52 | -5.49 | 55.53 | 1.67 | - | ||
| 2025/12 | 24.42 | 130.65 | 66.88 | 205.01 | 10.31 | 62.54 | 1.54 | 主要係本月份併購取得NAGH，受惠於其營收挹注所致 | ||
| 2025/11 | 10.59 | -61.54 | -0.17 | 180.59 | 5.48 | 50.25 | 1.92 | - | ||
| 2025/10 | 27.53 | 126.85 | 46.04 | 170.0 | 5.85 | 51.26 | 1.88 | - | ||
| 2025/9 | 12.14 | 4.62 | 2.25 | 142.48 | 0.5 | 47.71 | 0.82 | - | ||
| 2025/8 | 11.6 | -51.61 | -12.48 | 130.34 | 0.35 | 46.01 | 0.85 | - | ||
| 2025/7 | 23.97 | 129.56 | -11.92 | 118.74 | 1.8 | 45.71 | 0.86 | - | ||
| 2025/6 | 10.44 | -7.53 | -6.25 | 94.77 | 5.99 | 47.47 | 0.82 | - | ||
| 2025/5 | 11.29 | -56.11 | -27.25 | 84.33 | 7.73 | 52.94 | 0.73 | - | ||
| 2025/4 | 25.73 | 61.66 | 23.93 | 73.03 | 16.39 | 51.32 | 0.76 | - | ||
| 2025/3 | 15.92 | 64.65 | 38.34 | 47.3 | 12.66 | 47.3 | 0.81 | - | ||
| 2025/2 | 9.67 | -55.47 | -8.09 | 31.38 | 2.96 | 46.01 | 0.83 | - | ||
| 2025/1 | 21.71 | 48.38 | 8.8 | 21.71 | 8.8 | 46.95 | 0.82 | - | ||
| 2024/12 | 14.63 | 37.96 | 6.62 | 185.84 | 9.58 | 44.09 | 0.87 | - | ||
| 2024/11 | 10.61 | -43.73 | -6.55 | 171.21 | 9.85 | 41.32 | 0.93 | - | ||
| 2024/10 | 18.85 | 58.82 | 106.76 | 160.6 | 11.13 | 43.97 | 0.87 | 主係本月血癌用藥Lenalidomide於美國市場銷售量較去年同期增加所致 | ||
| 2024/9 | 11.87 | -10.45 | 7.85 | 141.75 | 4.7 | 52.34 | 0.76 | - | ||
| 2024/8 | 13.25 | -51.31 | 11.85 | 129.88 | 4.42 | 51.61 | 0.77 | - | ||
| 2024/7 | 27.22 | 144.35 | 18.97 | 116.63 | 3.63 | 53.89 | 0.74 | - | ||
| 2024/6 | 11.14 | -28.25 | 0.98 | 89.41 | -0.27 | 47.43 | 0.8 | - | ||
| 2024/5 | 15.53 | -25.22 | 17.48 | 78.27 | -0.45 | 47.79 | 0.8 | - | ||
| 2024/4 | 20.76 | 80.46 | 2.93 | 62.74 | -4.07 | 42.79 | 0.89 | - | ||
| 2024/3 | 11.51 | 9.37 | -19.55 | 41.98 | -7.19 | 41.98 | N/A | - | ||
| 2024/2 | 10.52 | -47.29 | -3.13 | 30.48 | -1.48 | 44.2 | N/A | - | ||
| 2024/1 | 19.96 | 45.41 | -0.59 | 19.96 | -0.59 | 45.03 | N/A | - | ||
| 2023/12 | 13.72 | 20.91 | 7.98 | 169.58 | 15.89 | 34.19 | N/A | - | ||
| 2023/11 | 11.35 | 24.5 | 5.94 | 155.86 | 16.64 | 31.47 | N/A | - | ||
| 2023/10 | 9.12 | -17.15 | 9.93 | 144.51 | 17.57 | 31.97 | N/A | - | ||
| 2023/9 | 11.0 | -7.12 | -67.14 | 135.39 | 18.12 | 45.73 | N/A | 本月營收較去年同期減少主係因去年血癌用藥集中於九月出貨基期較高，今年分散逐季出貨後，累計營收仍較去年同期成長。 | ||
| 2023/8 | 11.85 | -48.21 | 18.86 | 124.38 | 53.32 | 45.76 | N/A | 本年累計營業收入較去年同期增長係因本年度血癌用藥Lenalidomide於美國市場銷售量增加所致。 | ||
| 2023/7 | 22.88 | 107.4 | 119.22 | 112.54 | 58.15 | 47.13 | N/A | 主係血癌用藥Lenalidomide於美國市場銷售量增加所致 | ||
| 2023/6 | 11.03 | -16.52 | 5.99 | 89.66 | 47.66 | 44.42 | N/A | - | ||
| 2023/5 | 13.22 | -34.48 | 51.8 | 78.63 | 56.28 | 47.69 | N/A | 主係美國市場客戶戒毒癮藥及血癌用藥Lenalidomide銷量增加所致 | ||
| 2023/4 | 20.17 | 41.04 | 101.89 | 65.41 | 57.21 | 45.33 | N/A | 美國市場客戶血癌用藥Lenalidomide補貨所致 | ||
| 2023/3 | 14.3 | 31.7 | 20.52 | 45.24 | 43.09 | 45.24 | N/A | - | ||
| 2023/2 | 10.86 | -45.91 | 5.53 | 30.94 | 56.66 | 43.65 | N/A | 一月份美國市場客戶血癌用藥Lenalidomide補貨所致 | ||
| 2023/1 | 20.08 | 57.96 | 112.28 | 20.08 | 112.28 | 43.5 | N/A | 美國市場客戶血癌用藥Lenalidomide補貨所致 | ||
| 2022/12 | 12.71 | 18.63 | 39.03 | 146.33 | 15.68 | 31.72 | N/A | - | ||
| 2022/11 | 10.71 | 29.18 | 8.61 | 133.62 | 14.19 | 52.5 | N/A | - | ||
| 2022/10 | 8.29 | -75.23 | -4.48 | 122.9 | 14.7 | 51.75 | N/A | - | ||
| 2022/9 | 33.49 | 235.96 | 230.63 | 114.61 | 16.4 | 53.89 | N/A | 血癌用藥Lenalidomide本期在美國上市銷售 | ||
| 2022/8 | 9.97 | -4.48 | 6.38 | 81.12 | -8.16 | 30.81 | N/A | - | ||
| 2022/7 | 10.44 | 0.27 | -5.79 | 71.15 | -9.88 | 29.55 | N/A | - | ||
| 2022/6 | 10.41 | 19.55 | -9.51 | 60.72 | -10.55 | 29.1 | N/A | - | ||
| 2022/5 | 8.71 | -12.87 | -24.72 | 50.31 | -10.77 | 30.56 | N/A | - | ||
| 2022/4 | 9.99 | -15.8 | -13.67 | 41.61 | -7.16 | 32.15 | N/A | - | ||
| 2022/3 | 11.87 | 15.32 | 7.83 | 31.61 | -4.9 | 31.61 | N/A | - | ||
| 2022/2 | 10.29 | 8.78 | 1.27 | 19.75 | -11.2 | 28.89 | N/A | - | ||
| 2022/1 | 9.46 | 3.46 | -21.7 | 9.46 | -21.7 | 28.46 | N/A | - | ||
| 2021/12 | 9.14 | -7.32 | -9.59 | 126.15 | 17.58 | 27.69 | N/A | - | ||
| 2021/11 | 9.86 | 13.6 | 3.04 | 117.01 | 22.16 | 28.67 | N/A | - | ||
| 2021/10 | 8.68 | -14.27 | -15.15 | 107.14 | 24.28 | 28.18 | N/A | - | ||
| 2021/9 | 10.13 | 8.1 | -0.76 | 98.46 | 29.59 | 30.58 | N/A | - | ||
| 2021/8 | 9.37 | -15.42 | 25.26 | 88.33 | 34.32 | 31.95 | N/A | - | ||
| 2021/7 | 11.08 | -3.67 | -0.8 | 78.96 | 35.48 | 34.14 | N/A | - | ||
| 2021/6 | 11.5 | -0.55 | 9.3 | 67.89 | 44.08 | 0.0 | N/A | - | ||
| 2021/5 | 11.57 | -0.08 | 34.44 | 56.38 | 53.0 | 0.0 | N/A | 外銷戒癮含片之美國終端市場份額較去年同期大幅增加 |
| 加權平均股數 YoY | EPS YoY | 本業EPS YoY | 營收 YoY | 毛利率(%) YoY | 營業利益率 YoY | 稅後淨利率 YoY | 營業利益 YoY | 稅前淨利 YoY | 稅後淨利 YoY | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | 260 | -0.76 | 18.04 | -6.19 | 18.87 | 3.8 | 205.09 | 10.36 | 58.05 | -1.24 | 28.79 | -11.11 | 23.01 | -15.59 | 59.04 | -1.93 | 57.18 | -10.09 | 47.2 | -6.83 |
| 2024 (4) | 262 | 0.38 | 19.23 | 22.72 | 18.18 | 21.04 | 185.84 | 9.59 | 58.78 | 6.22 | 32.39 | 12.04 | 27.26 | 12.6 | 60.2 | 22.78 | 63.6 | 24.63 | 50.66 | 23.38 |
| 2023 (3) | 261 | 0.0 | 15.67 | 35.79 | 15.02 | 22.31 | 169.58 | 15.89 | 55.34 | 3.73 | 28.91 | 2.88 | 24.21 | 17.3 | 49.03 | 19.27 | 51.03 | 29.52 | 41.06 | 35.92 |
| 2022 (2) | 261 | 2.35 | 11.54 | 110.97 | 12.28 | 74.68 | 146.33 | 15.69 | 53.35 | 19.65 | 28.10 | 54.82 | 20.64 | 86.11 | 41.11 | 79.13 | 39.4 | 110.7 | 30.21 | 115.32 |
| 2021 (1) | 255 | 4.94 | 5.47 | 29.62 | 7.03 | 37.04 | 126.49 | 17.9 | 44.59 | 0 | 18.15 | 0 | 11.09 | 0 | 22.95 | 42.28 | 18.7 | 43.4 | 14.03 | 36.61 |